Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
Source: SeekingAlpha
2025-09-03 15:14:48 ET
More on Erasca, Xencor, etc.
- Candel Therapeutics announces $15M in direct offering
- Incyte granted FDA label expansion for lymphoma therapy Monjuvi
- Seeking Alpha’s Quant Rating on Erasca
- Historical earnings data for Erasca
- Financial information for Erasca
Read the full article on Seeking Alpha
For further details see:
Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
Xencor Inc.
NASDAQ: XNCR
XNCR Trading
-3.35% G/L:
$11.38 Last:
182,405 Volume:
$11.72 Open:
XNCR Latest News
XNCR Stock Data
$902,628,328
68,011,331
N/A
68
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
